Afya (AFYA) Set to Release Quarterly Earnings on Thursday

Key Points

• Afya is scheduled to report Q3 2026 results after market close on November 12; analysts expect earnings of $0.3791 per share and revenue of $190.41 million.
• In its previous quarter, Afya earned $0.43 per share, beating the $0.40 consensus, but revenue of $187.8 million fell short of expectations.
• Analyst views are mixed, with a consensus Hold rating and a $15.70 average price target; recent recommendations ranged from Buy to Sell.

Afya (NASDAQ:AFYA - Get Free Report) is anticipated to announce its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect Afya to post earnings of $0.3791 per share and revenue of $190.41 million for the quarter. Interested persons may visit the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 5:00 PM ET.

Afya (NASDAQ:AFYA - Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported $0.43 earnings per share for the quarter, topping analysts' consensus estimates of $0.40 by $0.03. Afya had a return on equity of 17.58% and a net margin of 20.55%. The business had revenue of $187.80 million for the quarter, compared to analysts' expectations of $189.62 million. On average, analysts expect Afya to post $1.72 EPS for the current fiscal year and $1.83 EPS for the next fiscal year.

Afya Price Performance

Shares of NASDAQ AFYA opened at $10.50 on Thursday. Afya has a 1-year low of $9.66 and a 1-year high of $16.16. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.20 and a quick ratio of 2.20. The business's fifty day moving average price is $13.40 and its two-hundred day moving average price is $14.14. The firm has a market capitalization of $984.06 million, a PE ratio of 5.99, a P/E/G ratio of 1.65 and a beta of 0.43.

Insider Transactions at Afya

In other news, insider Santos Welder Ferreira sold 4,161 shares of Afya stock in a transaction on Monday, October 5th. The stock was sold at an average price of $13.30, for a total transaction of $55,341.30. Following the transaction, the insider directly owned 35,000 shares in the company, valued at approximately $465,500. This trade represents a 10.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.80% of the company's stock.

Wall Street Analysts Forecast Growth

AFYA has been the subject of several analyst reports. JPMorgan Chase & Co. reduced their price target on shares of Afya from $19.00 to $17.50 and set an "overweight" rating for the company in a report on Tuesday. Citigroup raised shares of Afya from a "neutral" rating to a "buy" rating and dropped their price objective for the stock from $16.00 to $12.00 in a report on Tuesday. Weiss Ratings downgraded shares of Afya from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Thursday, October 29th. Zacks Research raised shares of Afya from a "strong sell" rating to a "hold" rating in a research note on Monday, October 5th. Finally, Wall Street Zen lowered shares of Afya from a "buy" rating to a "hold" rating in a research note on Saturday, October 31st. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $15.70.

About Afya

Afya Limited is a medical education and digital health company focused on Brazil. Through its educational platform, the company provides undergraduate medical education, medical residency preparation, specialization and continuing medical education programs, and other learning resources for students and physicians.

Afya also offers digital products and services intended to support healthcare professionals throughout their careers. These include clinical content, study tools, telemedicine and practice-management solutions, and subscription-based applications designed to assist physicians with education, clinical decision-making, and patient care.

The company has expanded through the development and acquisition of medical schools, education businesses, and health technology platforms serving different stages of the medical professional lifecycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.